New pill shows promise for controlling painful skin condition in long-term trial
NCT ID NCT07665437
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 study tests the long-term safety and effectiveness of remibrutinib, an oral drug, in 710 adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. Participants have already completed a prior remibrutinib study. The trial compares two doses and tracks side effects and reduction in skin lesions over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
remibrutinib (oral drug)
What this could lead to
If successful, this could provide a new long-term treatment option to control painful skin abscesses and inflammation in hidradenitis suppurativa.
What could go wrong
This is an extension study, so participants already tolerated the drug, but long-term safety and effectiveness are still being confirmed. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••